#USA #Milford #Waters Corporation #BioResolve Columns #GTxResolve Lipid

Waters Corporation's Game-Changing Bioseparation Technology

In a groundbreaking announcement at the 55th International Symposium on High-Performance Liquid Phase Separations and Related Techniques, Waters Corporation (NYSE: WAT) has unveiled its latest innovation: the BioResolve™ Peptide and GTxResolve™ Lipid reversed-phase columns. These cutting-edge columns have been designed to address a major challenge in biopharmaceutical development—separating structurally similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs).

Speeding Up Biopharmaceutical Development

The new columns promise to speed up the characterization of GLP-1 (Glucagon-like peptide-1) and enhance the analysis of LNP components, delivering up to three times faster results for GLP-1 analysis and twice the speed for LNP component analysis. This acceleration in testing can significantly reduce bottlenecks in production timelines, allowing biopharmaceutical companies to bring therapies to market much more quickly.

Currently, the complexity of GLP-1 receptor agonists and novel mRNA-based therapies presents challenges when it comes to identifying low-level impurities. Traditional reversed-phase (RP) columns frequently fall short in separating these closely related impurities, leading to longer analysis times and potential setbacks in regulatory confidence and patient safety. Waters' innovative columns are aimed specifically at overcoming these limitations.

A Leap in Analytical Precision

According to Erin Chambers, Vice President and General Manager at Waters Analytical Sciences, the new columns represent simultaneous advancements in both chemistry and particle physics. Specifically, they have undergone quality control (QC) batch testing for GLP-1 and LNP analyses, addressing longstanding concerns from customers about the reliability of existing methods. Employers can look forward to enhanced resolution, speed, and increased certainty in their results, thus elevating their regulatory readiness.

By optimizing surface chemistry and utilizing superficially porous particles, the BioResolve Peptide and GTxResolve Lipid columns provide highly selective RP separations for difficult sample types. The new technologies incorporate specially designed formats that cater to complex molecular structures lacking significant atomic differentiation, which often challenges current analytical methods.

Real-World Applications and Testimonials

Early feedback from industry leaders has been overwhelmingly positive. Ashish Kanhed, Group Leader at Alembic Pharmaceuticals, noted exceptional performance in distinguishing peptides from their impurities, stating, "We are highly impressed with their quality and look forward to using them for our complex GLP-1 and peptide separations."

Martin Kowalczyk, Research Scientist II at Acuitas Therapeutics, echoed this sentiment regarding the GTxResolve Lipid Columns. He pointed out how their ability to tune separations for specific lipid components enhances flexibility in analyzing different lipid species. Moreover, the new columns ensure improved peak shapes and short run times, fundamentally changing lipid quantification processes.

Future Availability and Support

The introduction of these revolutionary columns marks a significant milestone in the biopharmaceutical industry, which is ever more reliant on effective and precise analytical tools. The BioResolve Peptide and GTxResolve Lipid columns will be available globally starting June 9, 2026. With features that support mass transfer and consistent performance across various analytical settings, Waters aims to improve the path from drug development to patient administration.

For those interested in learning more, Waters has made detailed resources available on their website, including comprehensive product pages for the BioResolve and GTxResolve systems.

Through relentless innovation and a commitment to scientific excellence, Waters Corporation continues to drive significant improvements in life sciences, paving the way for the development of safe, effective therapeutic solutions worldwide.